JP2000507596A - Ｃｄ４▲上＋▼細胞のｈｉｖ―１感染を防ぐ方法 - Google Patents

Ｃｄ４▲上＋▼細胞のｈｉｖ―１感染を防ぐ方法

Info

Publication number
JP2000507596A
JP2000507596A JP9535610A JP53561097A JP2000507596A JP 2000507596 A JP2000507596 A JP 2000507596A JP 9535610 A JP9535610 A JP 9535610A JP 53561097 A JP53561097 A JP 53561097A JP 2000507596 A JP2000507596 A JP 2000507596A
Authority
JP
Japan
Prior art keywords
agent
cells
chemokine
hiv
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP9535610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507596A5 (enExample
Inventor
オールアウェイ、グラハム・ピー
リットウィン、バージニア・エム
マッドン、ポール・ジェイ
オルソン、ウィリアム・シー
Original Assignee
プロジェニクス・ファーマスーティカルス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロジェニクス・ファーマスーティカルス・インコーポレーテッド filed Critical プロジェニクス・ファーマスーティカルス・インコーポレーテッド
Publication of JP2000507596A publication Critical patent/JP2000507596A/ja
Publication of JP2000507596A5 publication Critical patent/JP2000507596A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP9535610A 1996-04-02 1997-04-02 Ｃｄ４▲上＋▼細胞のｈｉｖ―１感染を防ぐ方法 Withdrawn JP2000507596A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62768496A 1996-04-02 1996-04-02
US08/627,684 1996-04-02
US66361696A 1996-06-14 1996-06-14
US08/663,616 1996-06-14
US67368296A 1996-06-25 1996-06-25
US08/673,682 1996-06-25
PCT/US1997/005597 WO1997037005A1 (en) 1996-04-02 1997-04-02 Method for preventing hiv-1 infection of cd4+ cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007220275A Division JP2008069148A (ja) 1996-04-02 2007-08-27 Ｃｄ４＋細胞のｈｉｖ−１感染を防ぐ方法

Publications (2)

Publication Number Publication Date
JP2000507596A true JP2000507596A (ja) 2000-06-20
JP2000507596A5 JP2000507596A5 (enExample) 2004-12-09

Family

ID=27417425

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9535610A Withdrawn JP2000507596A (ja) 1996-04-02 1997-04-02 Ｃｄ４▲上＋▼細胞のｈｉｖ―１感染を防ぐ方法
JP2007220275A Withdrawn JP2008069148A (ja) 1996-04-02 2007-08-27 Ｃｄ４＋細胞のｈｉｖ−１感染を防ぐ方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007220275A Withdrawn JP2008069148A (ja) 1996-04-02 2007-08-27 Ｃｄ４＋細胞のｈｉｖ−１感染を防ぐ方法

Country Status (5)

Country Link
EP (1) EP0915969A4 (enExample)
JP (2) JP2000507596A (enExample)
AU (1) AU728512B2 (enExample)
CA (1) CA2250829A1 (enExample)
WO (1) WO1997037005A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501675A (ja) * 2007-10-24 2011-01-13 プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
ES2270461T3 (es) * 1996-06-03 2007-04-01 United Biomedical, Inc. Anticuerpos contra un complejo de cd4 y un dominio receptor de quemoquina, y sus usos contra las infecciones de vih.
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
FR2771423A1 (fr) * 1997-11-21 1999-05-28 Transgene Sa Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
US6399078B1 (en) 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
DE60041489D1 (de) * 1999-07-09 2009-03-19 Gen Probe Inc Nachweis von hiv-1 durch amplifizierung von nukleinsäuren
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
CA2922428A1 (en) 2013-08-29 2015-03-05 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for rna-guided treatment of hiv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
EP0854918A1 (en) * 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
EP0883687B1 (en) 1996-03-01 2004-10-27 Euroscreen S.A. C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN4007006221, Ｓｃｉｅｎｃｅ, １９９５， Ｖｏｌ．２７０, ｐｐ．１８１１−１８１５ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011501675A (ja) * 2007-10-24 2011-01-13 プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法

Also Published As

Publication number Publication date
EP0915969A4 (en) 2002-04-17
EP0915969A1 (en) 1999-05-19
AU2607497A (en) 1997-10-22
CA2250829A1 (en) 1997-10-09
AU728512B2 (en) 2001-01-11
WO1997037005A1 (en) 1997-10-09
JP2008069148A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
JP2008069148A (ja) Ｃｄ４＋細胞のｈｉｖ−１感染を防ぐ方法
US6344545B1 (en) Method for preventing HIV-1 infection of CD4+ cells
AU753362B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU735460B2 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
Blanpain et al. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein
FR2751658A1 (fr) Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
US20040086528A1 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
PL204231B1 (pl) Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza
US7935797B2 (en) CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion
Su et al. Inhibition of the expression and function of chemokine receptors on human CD4+ leukocytes by HIV-1 envelope protein gp120
JP4116087B2 (ja) 新規マウスｃｘｃケモカインレセプター
AU776239B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU2004233505B2 (en) Method for preventing HIV-1 infection of CD4+ cells
MXPA98010425A (en) Uses of a chemiocine receiver to inhibit theinfection with human immunodeficiency viruses
Agrawal et al. Chemokine receptors: emerging opportunities for new anti-HIV therapies
AU2004205143A1 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
HK1029520B (en) Method for preventing hiv-1 infection of cd4+ cells
WO2004053094A2 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090525

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100104

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20100308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100413

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100813